Phase 1 Lymphoma Trial, Recruiting NCT07106749 Sponsor: Institute of Hematology & Blood Diseases Hospital, China Condition: Lymphoma
Back to Lymphoma

Phase 1 Lymphoma Trial, Recruiting

NCT07106749
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are aged 18 or older but under 70 years old, of any gender
  • You have been diagnosed with a specific type of blood cancer called B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma (B-ALL/LBL), following standard diagnosis guidelines
  • You have been diagnosed with a type of blood cancer called acute myeloid leukemia (AML), following standard diagnosis guidelines
  • Lab tests have confirmed that your cancer cells carry a specific marker called CD180 on their surface
  • At least 5% of the cells in your bone marrow are abnormal (blast) cells, confirmed by bone marrow testing
  • Your AML has come back or has not responded to treatment, meeting at least one of these conditions: your cancer did not go into remission after two standard chemotherapy cycles; it came back within 12 months of remission; it came back after 12 months but did not respond to further chemotherapy; you have had two or more relapses; or it came back after a stem cell transplant
  • Your B-ALL/LBL has come back or has not responded to treatment, meeting at least one of several specific conditions (confirm with trial site)
  • You have another type of CD180-positive blood cancer that has returned or stopped responding to treatment (confirm with trial site)
  • Your kidneys, liver, and heart are functioning well enough to meet specific medical thresholds (confirm with trial site)
  • Your blood oxygen level is at least 92%
  • Your doctors expect you to live for more than 3 months
  • You are able to carry out basic daily activities, with a functional ability score of 0, 1, or 2 on a standard medical scale (confirm with trial site)
  • You (or your legal guardian) are willing to take part and have signed a consent form

Who may not be able to join:

  • You have a specific type of leukemia called acute promyelocytic leukemia (APL)
  • You have a genetic condition that causes bone marrow failure, such as Fanconi anemia, Kostmann syndrome, or Shwachman syndrome
  • You have leukemia that has spread to your central nervous system (brain and spinal fluid) and is not under control
  • You have received certain cancer treatments too recently before joining — including chemotherapy within the past week, certain antibody-based treatments within a specific timeframe, or a donor lymphocyte infusion within the past 6 weeks (confirm with trial site for exact timing)
  • You currently have a serious infection that is not under control
  • You have a significant heart condition, such as severe heart failure, a heart attack within the past 12 months, serious irregular heartbeat, or other major heart problems
  • You have had a serious brain or neurological condition — such as a head injury, epilepsy, stroke, or brain bleeding — that required treatment within the past 6 months
  • You have certain active infections including hepatitis B (at high levels), hepatitis C, HIV, syphilis, or a specific viral infection called EBV (confirm with trial site)
  • You need to take steroid medications by mouth or injection during the treatment period (inhaled or topical steroids may be acceptable — confirm with trial site)
  • You have an autoimmune disease requiring treatment, an immune deficiency, or you need medications that suppress your immune system
  • You have had a serious complication from a previous stem cell transplant called graft-versus-host disease (GvHD) within the past 4 weeks
  • You have had an allergic reaction to any ingredient in cell-based treatments
  • You are pregnant, breastfeeding, or unable or unwilling to use effective contraception for 1 year after treatment; or you or your partner are planning a pregnancy within 1 year after treatment
  • Your doctor determines there is any other reason that taking part may not be safe for you or may affect the trial results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Registry
ClinicalTrials.gov
Start date
28 June 2025
Est. completion
28 June 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Dose-limiting toxicity(DLT); Number of adverse event of CD180 CART cells treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov